Výsledky vyhledávání - "Bridgette Kanz Schroader"

Akademický článek

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant

Autor: Sikander Ailawadhi, Augustina Ogbonnaya, Sharanya Murty, Dasha Cherepanov, Bridgette Kanz Schroader, Dorothy Romanus, Eileen Farrelly, Ajai Chari

Publikováno v: Cancer Medicine, Vol 12, Iss 3, Pp 3145-3159 (2023)

Abstract Background Extended first‐line therapy (1LT) has improved clinical outcomes in newly diagnosed multiple myeloma (NDMM). This retrospective study of NDMM patients evaluated the relationship between dose‐attenuation of 1LT and duration of

Externí odkaz: https://doaj.org/article/0312cf2755424ff7996a082a257356af

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis

Autor: Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang

Publikováno v: Journal of Health Economics and Outcomes Research (2021)

**Background:** There are sparse data addressing whether standard risk factors for febrile neutropenia (FN) are relevant in patients receiving myelosuppressive chemotherapy and primary prophylaxis for FN, which would have implications for variables t

Externí odkaz: https://doaj.org/article/638d0aad450b43f6b24077fd901b0870

Zobrazit plný text záznamu

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant

Autor: Sikander Ailawadhi, Augustina Ogbonnaya, Sharanya Murty, Dasha Cherepanov, Bridgette Kanz Schroader, Dorothy Romanus, Eileen Farrelly, Ajai Chari

Publikováno v: Cancer Medicine. 12:3145-3159

Extended first-line therapy (1LT) has improved clinical outcomes in newly diagnosed multiple myeloma (NDMM). This retrospective study of NDMM patients evaluated the relationship between dose-attenuation of 1LT and duration of therapy (DOT) and DOT on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff28eeddc9bc304cfbfd8a08ff1a0718
https://doi.org/10.1002/cam4.5239

Zobrazit plný text záznamu

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis

Autor: Edward C. Li, Weijia Wang, David Campbell, Bridgette Kanz Schroader, Kim Campbell

Publikováno v: Journal of Health Economics and Outcomes Research (2021)
Journal of Health Economics and Outcomes Research

Background: There are sparse data addressing whether standard risk factors for febrile neutropenia (FN) are relevant in patients receiving myelosuppressive chemotherapy and primary prophylaxis for FN, which would have implications for variables to co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07146fea9eee0a451fc70635b6712bb7
https://jheor.scholasticahq.com/article/24564-the-impact-of-baseline-risk-factors-on-the-incidence-of-febrile-neutropenia-in-breast-cancer-patients-receiving-chemotherapy-with-pegfilgrastim-prophy.pdf

Zobrazit plný text záznamu

Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis

Autor: David Campbell, Edward C. Li, Weijia Wang, Bridgette Kanz Schroader, Kim Campbell, Ali McBride

Publikováno v: Journal of managed carespecialty pharmacy. 27(9)

BACKGROUND: Pegfilgrastim is available as a prefilled syringe (PFS) and an on-body injector (OBI). Whether the administration method of pegfilgrastim affects the effectiveness and health care resources has not been evaluated in the setting of routine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa64922f49a2dadb336743b7e4976bf1
https://pubmed.ncbi.nlm.nih.gov/33929269

Zobrazit plný text záznamu

Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia

Autor: Stephen Chaplin, Bridgette Kanz Schroader, Kimberley J. Campbell, Gary H. Lyman, Edward C. Li, David Campbell

Publikováno v: Journal of Clinical Oncology. 39:58-58

58 Background: The introduction of biosimilar colony-stimulating factors has led to the reduction in prices for these historically expensive therapies. To understand the impact of recent pricing trends on delivering efficient care, the cost-effective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be585ed131dad18580c2adb410fb7398
https://doi.org/10.1200/jco.2020.39.28_suppl.58

Zobrazit plný text záznamu